Simultaneous augmentation of muscle and bone by locomomimetism through calcium-PGC-1α signaling

Abstract

Impaired locomotion has been extensively studied worldwide because those afflicted with it have a potential risk of becoming bedridden. Physical exercise at times can be an effective remedy for frailty, but exercise therapy cannot be applied in all clinical cases. Medication is safer than exercise, but there are no drugs that reinforce both muscle and bone when administered alone. Multiple medications increase the risk of adverse events; thus, there is a need for individual drugs targeting both tissues. To this end, we established a novel sequential drug screening system and identified an aminoindazole derivative, locamidazole (LAMZ), which promotes both myogenesis and osteoblastogenesis while suppressing osteoclastogenesis. Administration of this drug enhanced locomotor function, with muscle and bone significantly strengthened. Mechanistically, LAMZ induced Mef2c and PGC-1α in a calcium signaling–dependent manner. As this signaling is activated upon physical exercise, LAMZ mimics physical exercise. Thus, LAMZ is a promising therapeutic drug for locomotor diseases, including sarcopenia and osteoporosis.

References

[1] Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants. Lancet Glob. Health, 2018, 6: e1077-e1086

[2] Guthold R, Stevens GA, Riley LM, Bull FC. Global trends in insufficient physical activity among adolescents: a pooled analysis of 298 population-based surveys with 1·6 million participants. Lancet Child Adolesc. Health, 2020, 4: 23-35

[3] Kohl HW et al. The pandemic of physical inactivity: global action for public health. Lancet, 2012, 380: 294-305

[4] WHO. Global action plan on physical activity 2018–2030: more active people for a healthier world. Geneva: World Health Organization (2018).

[5] Dennison EM, Sayer AA, Cooper C. Epidemiology of sarcopenia and insight into possible therapeutic targets. Nat. Rev. Rheumatol., 2017, 13: 340-347

[6] Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet, 2019, 393: 2636-2646

[7] Witham MD, Dodds RM. Hip fracture and sarcopenia: the need for a new paradigm in drug trials for older adults. Lancet Healthy Longev., 2021, 2: e234-e235

[8] Appelman-Dijkstra NM, Papapoulos SE. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nat. Rev. Endocrinol., 2018, 14: 605-623

[9] Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol, 2020, 16: 437-447

[10] Edwards MH, Dennison EM, Aihie Sayer A, Fielding R, Cooper C. Osteoporosis and sarcopenia in older age. Bone, 2015, 80: 126-130

[11] Greco EA, Pietschmann P, Migliaccio S. Osteoporosis and sarcopenia increase frailty syndrome in the elderly. Front. Endocrinol., 2019, 10: 255

[12] Wang DZ, Valdez MR, McAnally J, Richardson J, Olson EN. The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development. Development, 2001, 128: 4623-4633

[13] Hayashi, S., Manabe, I., Suzuki, Y., Relaix, F. & Oishi, Y. Klf5 regulates muscle differentiation by directly targeting muscle-specific genes in cooperation with MyoD in mice. Elife 5, e17462 (2016).

[14] Komori T et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 1997, 89: 755-764

[15] Ono T et al. IL-17-producing gammadelta T cells enhance bone regeneration. Nat. Commun., 2016, 7

[16] Kiviranta R et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone, 2005, 36: 159-172

[17] Sakai K, Miyazaki J-i. A transgenic mouse line that retains cre recombinase activity in mature oocytes irrespective of thecreTransgene transmission. Biochem. Biophys., 1997, 237: 318-324

[18] Nakamura T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell, 2007, 130: 811-823

[19] Ruas JL et al. A PGC-1alpha isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell, 2012, 151: 1319-1331

[20] Yu B et al. PGC-1alpha controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ. Cell Stem Cell, 2018, 23: 193-209 e195

[21] Li J et al. Modulation of an RNA-binding protein by abscisic-acid-activated protein kinase. Nature, 2002, 418: 793-797

[22] Gan Z, Fu T, Kelly DP, Vega RB. Skeletal muscle mitochondrial remodeling in exercise and diseases. Cell Res, 2018, 28: 969-980

[23] Zhang P et al. Cross-talk between phospho-STAT3 and PLCgamma1 plays a critical role in colorectal tumorigenesis. Mol. Cancer Res., 2011, 9: 1418-1428

[24] Hu J et al. Endothelin signaling activates Mef2c expression in the neural crest through a MEF2C-dependent positive-feedback transcriptional pathway. Development, 2015, 142: 2775-2780

[25] Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab., 2005, 1: 361-370

[26] Wu H et al. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J., 2001, 20: 6414-6423

[27] Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm. Regen., 2020, 40: 2

[28] Réda C, Kaufmann E, Delahaye-Duriez A. Machine learning applications in drug development. Computational Struct. Biotechnol. J., 2020, 18: 241-252

[29] Sasaki F, Hayashi M, Ono T, Nakashima T. The regulation of RANKL by mechanical force. J. Bone Min. Metab., 2021, 39: 34-44

[30] Rusnak F, Mertz P. Calcineurin: form and function. Physiological Rev., 2000, 80: 1483-1521

[31] Hudmon A, Schulman H. Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu. Rev. Biochem., 2002, 71: 473-510

[32] Michael LF et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. USA, 2001, 98: 3820-3825

[33] Czubryt MP, McAnally J, Fishman GI, Olson EN. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc. Natl. Acad. Sci. USA, 2003, 100: 1711-1716

[34] McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochemical Sci., 2002, 27: 40-47

[35] Liu N et al. Requirement of MEF2A, C, and D for skeletal muscle regeneration. Proc. Natl. Acad. Sci. USA, 2014, 111: 4109-4114

[36] Molkentin JD, Black BL, Martin JF, Olson EN. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell, 1995, 83: 1125-1136

[37] Arnold MA et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev. Cell, 2007, 12: 377-389

[38] Stephens AS et al. Myocyte enhancer factor 2c, an osteoblast transcription factor identified by dimethyl sulfoxide (DMSO)-enhanced mineralization. J. Biol. Chem., 2011, 286: 30071-30086

[39] Browe DC, Coleman CM, Barry FP, Elliman SJ. Hypoxia activates the PTHrP -MEF2C pathway to attenuate hypertrophy in mesenchymal stem cell derived cartilage. Sci. Rep., 2019, 9

[40] Nakatani T, Partridge NC. MEF2C interacts with c-FOS in PTH-stimulated Mmp13 gene expression in osteoblastic cells. Endocrinology, 2017, 158: 3778-3791

[41] Brusco J, Haas K. Interactions between mitochondria and the transcription factor myocyte enhancer factor 2 (MEF2) regulate neuronal structural and functional plasticity and metaplasticity. J. Physiol., 2015, 593: 3471-3481

[42] Khan AUH et al. Mitochondrial Complex I activity signals antioxidant response through ERK5. Sci. Rep., 2018, 8

[43] Puigserver P et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 1998, 92: 829-839

[44] Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev., 2004, 18: 357-368

[45] Zechner C et al. Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab., 2010, 12: 633-642

[46] Gill JF et al. Peroxisome proliferator-activated receptor gamma coactivator 1alpha regulates mitochondrial calcium homeostasis, sarcoplasmic reticulum stress, and cell death to mitigate skeletal muscle aging. Aging Cell, 2019, 18: e12993

[47] Tsuchiya Y et al. The key royal jelly component 10-hydroxy-2-decenoic acid protects against bone loss by inhibiting NF-kappaB signaling downstream of FFAR4. J Biol Chem, 2020, 295: 12224-12232

[48] Acosta JC et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol., 2013, 15: 978-990

[49] Sharabi K et al. Selective chemical inhibition of PGC-1alpha gluconeogenic activity ameliorates type 2 diabetes. Cell, 2017, 169: 148-160 e115

[50] Inoue M et al. Forceful mastication activates osteocytes and builds a stout jawbone. Sci. Rep., 2019, 9

[51] Kim Y et al. Suppression of hematopoietic cell kinase ameliorates the bone destruction associated with inflammation. Mod. Rheumatol., 2020, 30: 85-92

[52] Sasaki F et al. Mechanotransduction via the Piezo1-Akt pathway underlies Sost suppression in osteocytes. Biochem Biophys. Res Commun., 2020, 521: 806-813

[53] Ge SX, Son EW, Yao R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinforma., 2018, 19

Funding

Daiichi Sankyo Company (Sankyo Company)

Daiichi Sankyo Foundation of Life Science

Naito Foundation

Takeda Science Foundation

Suzuken Memorial Foundation